trial

Magnetic Seizure Therapy (MST) for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder

NCTId NCT01596608
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 224 (actual)
Sponsored by Centre for Addiction and Mental Health
Primary completion 2019-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
224 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2012-02
Primary completion
2019-06
Eligibility
ALL · 18 Years · 85 Years

Interventions & indications

Drugs
Magnetic Seizure Therapy (MagPro MST)

Sponsors

Centre for Addiction and Mental HealthLead Sponsor
University Health Network, TorontoCollaborator

Investigators

1
Z. Jeffrey Daskalakis, MD, PhD.Principal Investigator

Sites

1 total
Toronto, Canada

Facts & assertions

4 sourced
Enrollment
224
Phase
NA
Primary Completion Date
2019-06
Status
COMPLETED
relationships
The graph out of here
drug
Magnetic Seizure Therapy (MagPro MST)
drug
lead_sponsor
Centre for Addiction and Mental Health
company
collaborator
University Health Network, Toronto
company
indication
Depressive Disorder
indication
Depressive Disorder, Treatment-Resistant
indication
Schizoaffective Disorder
indication
investigator
Z. Jeffrey Daskalakis, MD, PhD.
person